









Markets
/
Stocks
/
nasdaq-cosm
/

Cosmos Health Inc

COSM

0.450USD

+0.010+2.23%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

14.33MMarket Cap

LossP/E TTM



Cosmos Health Inc

0.450

+0.010+2.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cosmos Health Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cosmos Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 3.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cosmos Health Inc's Score

Industry at a Glance

Industry Ranking

120 / 159

Overall Ranking

417 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cosmos Health Inc Highlights

StrengthsRisks

Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Growing

The company is in a growing phase, with the latest annual income totaling USD 54.43M.

Undervalued

The company’s latest PE is -0.59, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 235.74K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.15.

Analyst Rating

Based on 0 analysts

Current Rating

3.000

Target Price

+511.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cosmos Health Inc is 7.79, ranking 96 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 17.11M, representing a year-over-year increase of 37.86%, while its net profit experienced a year-over-year increase of 36.10%.

Score

Industry at a Glance

Previous score

7.79

Change



Financials

4.67

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.41

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cosmos Health Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cosmos Health Inc is 8.42, ranking 19 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.59, which is -92.83% below the recent high of -0.04 and -324.99% above the recent low of -2.51.

Score

Industry at a Glance

Previous score

8.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Cosmos Health Inc. The Pharmaceuticals industry's average is 7.85. The average price target is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cosmos Health Inc is 5.14, ranking 142 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.55 and the support level at 0.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.07

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Sell

RSI(14)

40.470

Neutral

STOCH(KDJ)(9,3,3)

22.386

Neutral

ATR(14)

0.047

Low Volatility

CCI(14)

-120.483

Sell

Williams %R

83.631

Oversold

TRIX(12,20)

-0.397

Sell

StochRSI(14)

52.016

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.457

Sell

MA10

0.474

Sell

MA20

0.490

Sell

MA50

0.502

Sell

MA100

0.714

Sell

MA200

0.649

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cosmos Health Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 8.69%, representing a quarter-over-quarter decrease of 13.88%. The largest institutional shareholder is The Vanguard, holding a total of 235.74K shares, representing 0.68% of shares outstanding, with 16.46% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Siokas (Grigorios)

6.72M

+3.98%

Bovopoulos (Andreas D)

1.45M

-22.74%

Terzis (Georgios)

727.26K

BlackRock Institutional Trust Company, N.A.

267.80K

The Vanguard Group, Inc.

Star Investors

235.74K

+74.84%

Citadel Advisors LLC

225.51K

+133.13%

Geode Capital Management, L.L.C.

198.68K

+3.72%

Renaissance Technologies LLC

Star Investors

92.80K

XTX Markets LLC

65.49K

+78.45%

Bardakis (Nikolaos)

45.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cosmos Health Inc is 1.87, ranking 143 out of 159 in the Pharmaceuticals industry. The company's beta value is 4.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.